H.R. 88: Medical Innovation Acceleration Act of 2025

The Medical Innovation Acceleration Act of 2025 aims to amend the Federal Food, Drug, and Cosmetic Act to exempt certain medical devices from regulatory oversight. Specifically, the bill focuses on non-invasive diagnostic devices, which are defined as those that:

• Do not penetrate the skin or any other membrane of the body
• Are not inserted or implanted into the body
• Only cause temporary effects, such as minor compression or temperature changes to bodily tissues
• Do not use ionizing radiation on bodily tissues

By removing regulatory burdens for non-invasive diagnostic devices, the bill aims to expedite their development and availability in the healthcare market. The intentions behind this legislative change include fostering innovation in medical technology, potentially allowing for quicker patient access to new diagnostic tools that can improve healthcare outcomes.

Key Points of the Bill

• The bill is specifically targeted at non-invasive diagnostic devices, which are generally perceived as lower-risk compared to invasive devices.
• This change seeks to streamline the approval process for these types of medical devices, possibly encouraging investment in medical technology.
• The bill explicitly defines what constitutes a non-invasive device, which may help in clarifying regulations for manufacturers.

Regulatory Impact

If this legislation passes, non-invasive diagnostic devices may no longer have to go through the same regulatory approval processes as other medical devices. This could lead to:

• Increased speed in bringing new diagnostic technologies to market
• Potential cost savings for manufacturers and, consequently, for consumers
• Encouragement for innovation in non-invasive diagnostic methods, impacting both startups and established companies specializing in medical devices

Potential Concerns

While the primary goal of the bill is to promote innovation, there could be concerns regarding:

• Patient safety and the adequacy of oversight for new diagnostic devices
• The effectiveness of non-invasive diagnostic methods that may not undergo rigorous testing

Relevant Companies

• TDOC - Teladoc Health may be impacted as they utilize diagnostic devices in telehealth settings.
• ABT - Abbott Laboratories, which has a division for diagnostic tools, may see an increase in innovation and product offerings.
• MDT - Medtronic is known for medical devices and may benefit from fewer regulatory hurdles for their non-invasive diagnostics.